2-(benzocyclobutan-1-yl)-1-bromoethane

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 2-(benzocyclobutan-1-yl)-1-bromoethane
• 英文别名: 7-(2-bromoethyl)bicyclo[4.2.0]octa-1,3,5-triene
• 化学式: C₁₀H₁₁Br
• 分子量: 211.101
• InChiKey: DAVBTLVZCQZAQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(2,3-二氢-1,4-苯并二烷-5-基)哌嗪盐酸盐 、 2-(benzocyclobutan-1-yl)-1-bromoethane 在 sodium carbonate 作用下， 以 various solvent(s) 为溶剂， 反应 24.0h， 生成 S 14489
  参考文献：
  名称：

  Characterization of Potent and Selective Antagonists at Postsynaptic 5-HT1A Receptors in a Series of N4-Substituted Arylpiperazines

  摘要：

  Benzocycloalkyl and benzocycloalkenyl moities linked, directly or via an alkyl chain, to oxygen-bearing heteroarylpiperazines were synthesized, in an attempt to obtain potent and selective antagonists at postsynaptic 5-HT1A receptors. From the numerous arylpiperazines described in the literature, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)pipe (3a) was chosen as a model of an arylpiperazine in view of its selectivity for 5-HT1A receptors versus alpha(1)-, alpha(2)-, and beta-adrenergic receptors, as well as dopamine D-1 and D-2 receptors. Two other closely-related arylpiperazines, 1-(1,5-benzodioxepin-6-yl)piperazine (3b) and 1-(benzofuran-7-yl)piperazine (3c), were also examined in this study. Al compounds showed high affinity at 5-HT1A sites (8.10 less than or equal to pK(i)s less than or equal to 9.35), and the majority behaved as antagonists in vivo in blocking the hypothermia induced by the 5-HT1A agonist 8-OH-DPAT in the absence of a marked effect alone at equivalent doses. An in vivo evaluation of dopamine D-2 receptor antagonist properties revealed that the majority of compounds was devoid of activity at this site, in marked contrast to BMY 7378 which displayed virtually no selectivity for 5-HT1A versus dopamine D-2 receptors. Moreover, six compounds of the present series, 8, 10, 11, 14, 25, and, 37, showed > 10-fold selectivity in vitro for 5-HT1A versus alpha(1)-adrenergic receptors. Compound 14 displayed an optimal compromise between potency (pK(i) = 8.75), marked antagonist activity, and selectivity toward alpha(1)-adrenergic (81-fold) and dopamine D-2 (195-fold) receptors. These characteristics clearly distinguish 14 from previously-reported ligands such as the postsynaptic 5-HT1A antagonist BMY 7378 and the weak partial agonist NAN 190 which, in contrast to the compounds of this series, belong to the well-exemplified class of imido derivatives of (o-methoxyphenyl)piperazines. The availability of 14 (S 15535) should facilitate the further elucidation of the functional role and potential therapeutic significance of 5-HT1A receptors.

  DOI：

  10.1021/jm00020a020

文献信息

• Piperazine, piperidine and 1,2,5,6-tetrahydropyridine
  申请人：Adir et Compagnie

  公开号：US05684020A1

  公开（公告）日：1997-11-04

  A compound selected from those of formula: ##STR1## wherein: A-B, n, D and E are as defined in the specification, their racemic mixtures, and their optical isomers, and also the physiologically tolerable salts thereof with appropriate acids. The products of the invention may be used therapeutically.

  从以下式中选择的化合物：##STR1## 其中：A-B，n，D和E如规范中定义，它们的外消旋混合物，以及它们的光学异构体，以及与适当酸的生理耐受盐。本发明的产品可用于治疗。
• Nouveaux composés de la pipérazine, de la pipéridine et de la 1,2,5,6-tétra-hydropyridine, leur procédé de préparation et les compositions pharmaceutiques les contenant
  申请人：ADIR ET COMPAGNIE

  公开号：EP0745598A1

  公开（公告）日：1996-12-04

  Les composés de formule I: dans laquelle A-Breprésente: CH2-CH, CH=C ou CH2-N, nreprésente zéro ou un nombre entier de 1 à 6 inclus, Dreprésente l'un des systèmes bicycliques suivants: dans lesquels: R1 et R2, identiques ou différents, représentent chacun un atome d'hydrogène ou d'halogène, un radical alkyle ou alkoxy en chaîne droite ou ramifiée ayant de 1 à 5 atomes de carbone inclus ou un radical hydroxy; et E représente un des hétérocycles suivants: leurs formes de mélange racémique ou racémate et d'isomères optiques ou énantiomères, ainsi que leurs sels avec des acides pharmaceutiquement acceptables. Les produits de l'invention peuvent être utilisés en thérapeutique.

  式 I 的化合物 其中 A-B代表：CH2-CH、CH=C 或 CH2-N、 n 代表零或 1 至 6（含 6）的整数、 D 代表下列双环体系之一： 其中 R1 和 R2（可以相同或不同）分别代表氢原子或卤素原子、具有 1 至 5 个碳原子 （含 5 个）的直链或支链烷基或烷氧基或羟基；以及 E 代表下列杂环之一： 它们的外消旋体或外消旋体混合物以及光学异构体或对映体形式、 及其与药学上可接受的酸的盐类。 本发明的产品可用于治疗。
• US5194437A
  申请人：——

  公开号：US5194437A

  公开（公告）日：1993-03-16
• US5684020A
  申请人：——

  公开号：US5684020A

  公开（公告）日：1997-11-04
• US5753662A
  申请人：——

  公开号：US5753662A

  公开（公告）日：1998-05-19